nach oben

Erschienen in:

01.02.2013 | Neuro

Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status

verfasst von: Andrea Romano, L. F. Calabria, F. Tavanti, G. Minniti, M. C. Rossi-Espagnet, V. Coppola, S. Pugliese, D. Guida, G. Francione, C. Colonnese, L. M. Fantozzi, A. Bozzao

Erschienen in: European Radiology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate whether apparent diffusion coefficient (ADC) values can predict the status of MGMT of glioblastoma multiforme (GBM) and correlate with overall survival (OS) and progression-free survival (PFS).

Methods

This retrospective study included 47 patients with pathologically proven glioblastoma. All of them underwent MR DWI study before surgery (mean time 1 week) and the status of methylguanine-DNA-methyltransferase (MGMT) promoter methylation was searched for. Minimum apparent diffusion coefficient (ADC) values were evaluated. OS and PSF parameters were calculated, and Student’s t-test, Kaplan-Meier curves, linear and Cox regression were performed.

Results

Twenty-five patients showed positive methylation of the MGMT promoter. Patients showing MGMT promoter methylation had higher minimum ADC values, and they survived longer than those without MGMT promoter methylation. The median ADCmin value of 0.80 represents the cutoff value able to distinguish between methylated and un-methylated patients. Patients showing minimum ADC values higher than 0.80 survived longer than patients with minimum ADC values lower than 0.80. A linear correlation between minimum ADC values vs. the OS and PFS was observed.

Conclusions

Minimum ADC values in glioblastoma multiforme could be used as a preoperative parameter to estimate the status of MGMT promoter methylation and the survival of patients.

Key Points

• Diffusion-weighted MR imaging (DWI) provides new insights into glioblastoma multiforme (GBM)

• DWI ADCmin values can predict the methylation status of MGMT promoter.

• The MGMT promoter methylation group survived longer than the unmethylated group.

• Patients with high ADCmin values survived longer than patients with low values.

Hegi E, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6 methylguanine—DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 6:1871–1874CrossRef

Rivera AL, Pelloski CE, Gilbert MR et al (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neurooncology 2:116–121

Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 10:997–1003CrossRef

Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933–4938PubMedCrossRef

Idbaih A, Omuro A, Ducray F, Hoang-Xuan K (2007) Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 19:606–611PubMedCrossRef

Eoli M, Menghi F, Bruzzone MG, De Simone T, Valletta L (2007) Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 9:2606–2613CrossRef

Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 25:4189–4199CrossRef

Weller M, Stupp R, Reifenberger G et al (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39–51PubMedCrossRef

Arvinda HR, Kesavadas C, Sarma PS et al (2009) Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol 94:87–96PubMedCrossRef

10.

Barajas RF, Hodgson G, Chang JS, Vandenberg SR, Yeh RF, Parsa AT (2010) Glioblastoma multiforme regional genetic and cellular expression patterns: Influence on anatomic and physiologic MR imaging. Radiology 2:564–576CrossRef

11.

Oh J, Henry RG, Pirzkall P et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline to N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19:546–554PubMedCrossRef

12.

Higano S, Yun X, Kumabe T, Watanabe M, Mugikura S (2006) Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 3:839–846CrossRef

13.

Moon WJ, Choi JW, Roh HG, Lim SD, Koh YC (2012) Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology 54:555–563 yPubMedCrossRef

14.

MacDonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMed

15.

Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81–83PubMedCrossRef

16.

17.

Minniti G, Amelio D, Amichetti M et al (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 3:377–381CrossRef

18.

Rock K, McArdle O, Forde P et al (2012) A clinical review of treatment outcomes in glioblastoma multiforme. The validation in a non-trial population of the results of a randomised phase III clinical trial: has a more radical approach improved survival? Br J Radiol. doi:10.1259/bjr/83796755

19.

Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388–2399PubMedCrossRef

20.

Silber JR, Blank A, Bobola MS et al (1999) O6-Methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5:807–814PubMed

21.

Murakami R, Sugahara T, Nakamura H, Hirai T, Kitajima M, Hayashida Y (2007) Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2:493–499CrossRef

22.

Bulakbasi N, Guvenc I, Onguru O et al (2004) The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors. J Comput Assist Tomogr 28:735–746PubMedCrossRef

23.

Yang D, Korogi Y, Sugahara T et al (2002) Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 44:656–666PubMedCrossRef

24.

Yamasaki F, Kurisu K, Satoh K et al (2005) Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 235:985–991PubMedCrossRef

25.

Watanabe T, Katayama Y, Komine C et al (2005) O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113:581–587PubMedCrossRef

26.

Brandes AA, Franceschi E, Tosoni A et al (2008) MGMTpromoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197PubMedCrossRef

27.

Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410PubMedCrossRef

28.

Brandes AA, Tosoni A, Spagnolli F et al (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. J Neurooncol 10:361–367

29.

Drabycz S, Roldán G, De Robles P et al (2010) An analysis of image texture, tumour location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. NeuroImage 2:1398–1405CrossRef

30.

Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60PubMedCrossRef

31.

Gupta RK, Cloughesy TF, Sinha U et al (2000) Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 50:215–226PubMedCrossRef

32.

Pope WB, Qiao XJ, Kim HJ et al (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 108:491–498PubMedCrossRef

33.

Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S et al (2006) Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 3:394–403CrossRef

34.

Kono K, Inoue Y, Nakayam K et al (2001) The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol 22:1081–1088PubMed

Titel: Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status
verfasst von: Andrea Romano
L. F. Calabria
F. Tavanti
G. Minniti
M. C. Rossi-Espagnet
V. Coppola
S. Pugliese
D. Guida
G. Francione
C. Colonnese
L. M. Fantozzi
A. Bozzao
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 2/2013
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-012-2601-4

Neu im Fachgebiet Radiologie

08.04.2024 | Andrologie | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status

Abstract

Objective

Methods

Results

Conclusions

Key Points

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Fat deposition decreases diffusion parameters at MRI: a study in phantoms and patients with liver steatosis

Assessment of grating-based X-ray phase-contrast CT for differentiation of invasive ductal carcinoma and ductal carcinoma in situ in an experimental ex vivo set-up

Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases

Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter

Reproducibility of 3D delayed gadolinium enhanced MRI of cartilage (dGEMRIC) of the knee at 3.0 T in patients with early stage osteoarthritis

Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines

Neu im Fachgebiet Radiologie

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Quantitative Angiografie könnte IVUS-Alternative darstellen

Die Ganz-Genom-Sequenzierung startet

Update Radiologie